Modine Manufacturing Company vs State Street SPDR S&P Biotech ETF — how do they compare? Modine Manufacturing Company trades at $245.92 (market cap $12.18B), while State Street SPDR S&P Biotech ETF trades at $154.4. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals.
| MOD | XBI | |
|---|---|---|
Market Cap | $12.18B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $306.89 | $164.28 |
52-Week Low | $93.71 | $85.16 |
Enterprise Value | $12.54B | — |
Signals from Pluang's Aura AI — not financial advice
MOD trades at $227.88, down 0.64% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.71 exceeding expectations. Revenue reached $2.58B in 2025, though net income margin is modest at 3.82%. Recent news includes institutional buying and executive appointments, while technical support sits near $221.
Analyst consensus is bullish with a $328.80 price target, but high P/E of 101.48 suggests premium valuation. Risks include margin pressure from supply chain challenges and competitive threats in data center cooling. The stock offers growth potential if margin expansion continues, but investors face volatility from technical weakness and execution risks.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →